Sparks commentary - Biomea Fusion

Healthcare

Sparks - Biomea Fusion

More on this equity
Biomea Fusion’s (NASDAQ: BMEA) icovamenib shows promise in severe insulin-deficient diabetes
Published by Arron Aatkar, PhD

Biomea Fusion has reported new preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies & Treatments for Diabetes 2025 conference. Notably, the data showed that, three months after the final dose of icovamenib, patients showed significant improvements in pancreatic beta-cell function, associated with a mean increase of 53% in C-peptide levels (a measure of glucose-dependent insulin secretion). The sustained effects of the therapy post-treatment highlight the potential of icovamenib as a possible disease-modifying treatment option for patients with severe insulin-deficient diabetes.

Latest

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free